Oaktree Acquisition Corp. III Life Sciences (NASDAQ:OACC) Stock Price Down 0.2% – Time to Sell?

Oaktree Acquisition Corp. III Life Sciences (NASDAQ:OACC)’s stock price dropped 0.2% during mid-day trading on Tuesday . The stock traded as low as $10.70 and last traded at $10.6750. Approximately 163 shares changed hands during mid-day trading, a decline of 64% from the average daily volume of 450 shares. The stock had previously closed at $10.70.

Analysts Set New Price Targets

Separately, Weiss Ratings reaffirmed a “sell (d)” rating on shares of Oaktree Acquisition Corp. III Life Sciences in a research note on Thursday, April 2nd. One investment analyst has rated the stock with a Sell rating, According to MarketBeat.com, the stock has an average rating of “Sell”.

Oaktree Acquisition Corp. III Life Sciences Trading Down 0.5%

The company has a 50 day moving average of $10.65 and a 200-day moving average of $10.63.

Oaktree Acquisition Corp. III Life Sciences (NASDAQ:OACC) last posted its earnings results on Thursday, March 26th. The company reported $0.08 earnings per share (EPS) for the quarter.

Hedge Funds Weigh In On Oaktree Acquisition Corp. III Life Sciences

Several hedge funds have recently bought and sold shares of the company. Empyrean Capital Partners LP lifted its stake in Oaktree Acquisition Corp. III Life Sciences by 20.0% during the 4th quarter. Empyrean Capital Partners LP now owns 900,000 shares of the company’s stock worth $9,522,000 after acquiring an additional 150,000 shares in the last quarter. Lighthouse Investment Partners LLC increased its holdings in Oaktree Acquisition Corp. III Life Sciences by 88.9% during the 2nd quarter. Lighthouse Investment Partners LLC now owns 850,000 shares of the company’s stock worth $8,882,000 after purchasing an additional 400,000 shares during the period. Sculptor Capital LP increased its holdings in Oaktree Acquisition Corp. III Life Sciences by 6.1% during the 4th quarter. Sculptor Capital LP now owns 530,537 shares of the company’s stock worth $5,613,000 after purchasing an additional 30,537 shares during the period. Goldman Sachs Group Inc. purchased a new stake in Oaktree Acquisition Corp. III Life Sciences during the 1st quarter worth about $5,417,000. Finally, Moore Capital Management LP purchased a new stake in Oaktree Acquisition Corp. III Life Sciences during the 2nd quarter worth about $5,502,000.

About Oaktree Acquisition Corp. III Life Sciences

Oaktree Acquisition Corp. III Life Sciences (NASDAQ: OACC) is a special purpose acquisition company (“SPAC”) formed to pursue merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combinations with one or more businesses in the life sciences sector. Incorporated as a Cayman Islands exempted company, OACC is sponsored by Oaktree Capital Management, a global alternative investment firm with a longstanding track record in credit strategies and private equity.